#novel approaches in cancer study | Explore Tumblr posts and blogs

bbmct · 3 days ago

Text

BBMCT: Set Up New Medical Research at AIIMS Hospital

British Biomedicine Clinical Trials (BBMCT) has become a pivotal player in advancing clinical research at prestigious medical institutions like the All India Institute of Medical Sciences (AIIMS) Hospital. As the medical field continues to evolve, collaboration with global leaders in clinical trials plays an essential role in driving progress. BBMCT, through its expert partnerships, has been instrumental in setting up new medical research at AIIMS Hospital, enriching patient care, accelerating innovation, and fostering collaborations that enhance the future of healthcare.

In this blog post, we will delve into the multiple ways in which BBMCT contributes to AIIMS Hospital’s research, its impact on patient care, and the broader medical community. The following subheadings will explore how BBMCT facilitates advancements in medical research at AIIMS and beyond.

## Enhances Patient Care and Outcomes

BBMCT plays a crucial role in improving patient care and outcomes by facilitating clinical trials that bring new treatments and therapies to the forefront. These trials not only help test the safety and efficacy of medical interventions but also give patients access to cutting-edge therapies that are not yet widely available. By setting up new clinical research initiatives at AIIMS Hospital, BBMCT ensures that patients receive the best possible care while contributing to the global understanding of disease management.

Furthermore, the data generated from clinical trials at AIIMS aids in creating tailored treatment plans for patients, improving long-term health outcomes. This personalized approach enhances the hospital’s capacity to treat complex conditions, such as cancer, cardiovascular diseases, and autoimmune disorders.

## Accelerates the Progress of Innovations

BBMCT has been instrumental in accelerating the progress of medical innovations at AIIMS Hospital. Through well-structured clinical trials, BBMCT supports the testing of novel drugs, medical devices, and treatment protocols. This fast-tracks the transition of groundbreaking innovations from laboratory research to real-world applications, benefiting patients and healthcare professionals alike.

Innovations in personalized medicine, gene therapy, and immunotherapy are among the key areas that BBMCT fosters at AIIMS. By supporting these cutting-edge studies, BBMCT plays a pivotal role in reshaping the future of healthcare by bringing innovative solutions to the clinical setting faster than traditional research timelines would allow.

## Establishes Partnerships with Leading Institutions

One of BBMCT’s core strengths is its ability to form strategic partnerships with leading medical institutions globally. This enables AIIMS Hospital to collaborate with renowned experts and access state-of-the-art research tools and resources. By creating these collaborative networks, BBMCT ensures that research conducted at AIIMS benefits from the latest global insights and methodologies.

These partnerships are essential in setting up new medical research projects, particularly in areas that require specialized expertise. Moreover, they help strengthen AIIMS’s position as a hub for advanced medical research in India, ensuring that the hospital remains at the forefront of global healthcare developments.

## Fills Significant Gaps in Knowledge

A major benefit of BBMCT’s involvement in clinical trials is its ability to fill critical gaps in medical knowledge. Despite significant advances in medicine, many diseases still lack effective treatments, and there are numerous unexplored areas in patient care. By facilitating clinical research at AIIMS Hospital, BBMCT provides a platform for addressing these gaps.

Research conducted through BBMCT often focuses on rare diseases, emerging health threats, and under-researched conditions, where traditional research may fall short. This focus allows AIIMS to contribute valuable insights into both common and niche medical conditions, benefiting not only Indian patients but the global population.

## Secures Funding for Research Projects

Conducting world-class clinical research requires substantial funding. BBMCT’s involvement at AIIMS Hospital significantly enhances the institution’s ability to secure grants and funding for critical medical research projects. The collaboration between BBMCT and AIIMS Hospital has attracted international funding from government agencies, private organizations, and philanthropic entities, ensuring that research can be carried out without financial constraints.

This funding also enables AIIMS to invest in state-of-the-art equipment, recruit top-tier researchers, and scale up promising research initiatives. The financial support secured by BBMCT ensures that AIIMS remains a leader in cutting-edge healthcare research in India.

## Improves the Institution’s Academic Reputation

AIIMS Hospital is renowned for its academic excellence, and BBMCT’s partnership further enhances its reputation as a leading institution in clinical research. By conducting high-quality clinical trials in collaboration with BBMCT, AIIMS attracts international attention, allowing it to recruit world-class researchers and practitioners to its team.

Furthermore, the findings from clinical trials conducted at AIIMS contribute to scientific literature, enhancing the institution’s academic standing. As a result, AIIMS becomes a sought-after partner for other research organizations and institutions looking to collaborate on innovative medical studies.

## Promotes Collaboration Among Research Teams

BBMCT’s involvement in clinical trials fosters a culture of collaboration among researchers, healthcare professionals, and experts from various fields. AIIMS Hospital, with its multidisciplinary approach to healthcare, greatly benefits from this collaboration. Researchers working on clinical trials, pharmaceutical companies, healthcare providers, and other stakeholders come together to achieve shared goals, ultimately advancing the field of medicine.

Collaboration also promotes knowledge exchange and the sharing of resources, making it easier to tackle complex medical problems. This networked approach accelerates the pace of discovery, ensuring that treatments and therapies are developed more efficiently.

## Supports Advancements Based on Evidence

BBMCT ensures that all clinical trials at AIIMS Hospital are rooted in evidence-based research. By relying on scientifically sound methodologies, the trials conducted through this collaboration lead to reliable and valid results that can be generalized to larger patient populations. This evidence-based approach is crucial in ensuring that any new treatment or therapy tested at AIIMS is not only safe but also effective.

Furthermore, this reliance on evidence supports informed decision-making in the medical field, providing healthcare providers with the information they need to offer the best care to their patients. It also plays a role in shaping public health policies based on proven data.

/media/fe48b75114c4a7ccf24b7775c9477286

— -

### FAQs About BBMCT and Its Role at AIIMS Hospital

**1. What is BBMCT’s role at AIIMS Hospital?**

BBMCT (British Biomedicine Clinical Trials) plays a crucial role in facilitating advanced clinical research at AIIMS Hospital by organizing and supporting clinical trials. These trials test new drugs, medical devices, and treatment protocols, enhancing patient care, improving health outcomes, and accelerating medical innovations. Through BBMCT’s partnership, AIIMS benefits from expertise, global collaborations, and increased funding for research.

**2. How does BBMCT improve patient outcomes?**

BBMCT improves patient outcomes by providing access to cutting-edge treatments that are still in clinical trial phases. Patients participating in these trials receive advanced medical care that might not be available through traditional treatment routes. The trials help test new therapies that can ultimately lead to better, more effective treatments for various diseases, improving long-term health outcomes.

**3. What innovations does BBMCT support at AIIMS?**

BBMCT supports a variety of innovative medical treatments at AIIMS, including advancements in gene therapy, immunotherapy, and personalized medicine. Through its clinical trials, BBMCT accelerates the development of new drugs, medical devices, and technologies, contributing to the advancement of healthcare solutions that address complex medical conditions such as cancer, cardiovascular diseases, and chronic illnesses.

**4. How does BBMCT help AIIMS secure research funding?**

BBMCT plays an essential role in helping AIIMS secure funding by attracting grants and sponsorships from government agencies, private foundations, and international research organizations. These funds are crucial for supporting the infrastructure and operations of clinical trials, ensuring that AIIMS remains equipped to conduct high-quality research that leads to breakthrough medical discoveries.

**5. How do BBMCT’s partnerships benefit AIIMS Hospital?**

BBMCT’s partnerships with leading medical institutions and research organizations enhance AIIMS’s ability to access cutting-edge research techniques, resources, and global expertise. These collaborations foster knowledge exchange, expand research opportunities, and improve the overall quality of research at AIIMS, helping the institution stay at the forefront of medical advancements.

— -

### Conclusion

British Biomedicine Clinical Trials (BBMCT) has been instrumental in advancing clinical research at AIIMS Hospital, contributing to improved patient care, faster medical innovations, and a stronger academic reputation for the institution. Through strategic partnerships, evidence-based research, and enhanced funding opportunities, BBMCT has positioned AIIMS as a leader in healthcare research. The collaborative spirit fostered by BBMCT ensures that AIIMS continues to make significant contributions to medical science, ultimately benefiting both Indian and global populations. With the continued support of BBMCT, AIIMS Hospital is poised to lead the way in groundbreaking medical research and patient care for years to come.

Subscribe to BBMCLINICALTRIALS YouTube channel for Research Insights

Be sure to subscribe to the **BBMCLINICALTRIALS YouTube channel** for exclusive access to the latest updates and in-depth insights into British Biomedicine Clinical Trials (BBMCT). Stay informed on cutting-edge research, clinical trial advancements, patient safety protocols, and breakthrough therapies being tested at AIIMS Hospital. Our channel provides expert discussions, industry trends, and detailed videos on the clinical trial process across various therapeutic areas. Whether you’re a healthcare professional, researcher, or simply interested in biomedical innovation, subscribing will keep you at the forefront of clinical research developments. Don’t miss out — join our community today!

#anya mouthwashing #artists on tumblr #agatha harkness #bucktommy #batman #cats of tumblr #captain curly #agatha all along #911 abc

3 notes · View notes

myrawjcsmicasereports · 30 days ago

Text

Inhibition of EIF4E Downregulates VEGFA and CCND1 Expression to Suppress Ovarian Cancer Tumor Progression by Jing Wang in Journal of Clinical Case Reports Medical Images and Health Sciences

Abstract

This study investigates the role of EIF4E in ovarian cancer and its influence on the expression of VEGFA and CCND1. Differential expression analysis of VEGFA, CCND1, and EIF4E was conducted using SKOV3 cells in ovarian cancer patients and controls. Correlations between EIF4E and VEGFA/CCND1 were assessed, and three-dimensional cell culture experiments were performed. Comparisons of EIF4E, VEGFA, and CCND1 mRNA and protein expression between the EIF4E inhibitor 4EGI-1-treated group and controls were carried out through RT-PCR and Western blot. Our findings demonstrate elevated expression of EIF4E, VEGFA, and CCND1 in ovarian cancer patients, with positive correlations. The inhibition of EIF4E by 4EGI-1 led to decreased SKOV3 cell clustering and reduced mRNA and protein levels of VEGFA and CCND1. These results suggest that EIF4E plays a crucial role in ovarian cancer and its inhibition may modulate VEGFA and CCND1 expression, underscoring EIF4E as a potential therapeutic target for ovarian cancer treatment.

Keywords: Ovarian cancer; Eukaryotic translation initiation factor 4E; Vascular endothelial growth factor A; Cyclin D1

Introduction

Ovarian cancer ranks high among gynecological malignancies in terms of mortality, necessitating innovative therapeutic strategies [1]. Vascular endothelial growth factor (VEGF) plays a pivotal role in angiogenesis, influencing endothelial cell proliferation, migration, vascular permeability, and apoptosis regulation [2, 3]. While anti-VEGF therapies are prominent in malignancy treatment [4], the significance of cyclin D1 (CCND1) amplification in cancers, including ovarian, cannot be overlooked, as it disrupts the cell cycle, fostering tumorigenesis [5, 6]. Eukaryotic translation initiation factor 4E (EIF4E), central to translation initiation, correlates with poor prognoses in various cancers due to its dysregulated expression and activation, particularly in driving translation of growth-promoting genes like VEGF [7, 8]. Remarkably, elevated EIF4E protein levels have been observed in ovarian cancer tissue, suggesting a potential role in enhancing CCND1 translation, thereby facilitating cell cycle progression and proliferation [9]. Hence, a novel conjecture emerges: by modulating EIF4E expression, a dual impact on VEGF and CCND1 expression might be achieved. This approach introduces an innovative perspective to impede the onset and progression of ovarian cancer, distinct from existing literature, and potentially offering a unique therapeutic avenue.

Materials and Methods

Cell Culture

Human ovarian serous carcinoma cell line SKOV3 (obtained from the Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences) was cultured in DMEM medium containing 10% fetal bovine serum. Cells were maintained at 37°C with 5% CO2 in a cell culture incubator and subcultured every 2-3 days.

Three-Dimensional Spheroid Culture

SKOV3 cells were prepared as single-cell suspensions and adjusted to a concentration of 5×10^5 cells/mL. A volume of 0.5 mL of single-cell suspension was added to Corning Ultra-Low Attachment 24-well microplates and cultured at 37°C with 5% CO2 for 24 hours. Subsequently, 0.5 mL of culture medium or 0.5 mL of EIF4E inhibitor 4EGI-1 (Selleck, 40 μM) was added. After 48 hours, images were captured randomly from five different fields—upper, lower, left, right, and center—using an inverted phase-contrast microscope. The experiment was repeated three times.

GEPIA Online Analysis

The GEPIA online analysis tool (http://gepia.cancer-pku.cn/index.html) was utilized to assess the expression of VEGFA, CCND1, and EIF4E in ovarian cancer tumor samples from TCGA and normal samples from GTEx. Additionally, Pearson correlation coefficient analysis was employed to determine the correlation between VEGF and CCND1 with EIF4E.

RT-PCR

RT-PCR was employed to assess the mRNA expression levels of EIF4E, VEGF, and CCND1 in treatment and control group samples. Total RNA was extracted using the RNA extraction kit from Vazyme, followed by reverse transcription to obtain cDNA using their reverse transcription kit. Amplification was carried out using SYBR qPCR Master Mix as per the recommended conditions from Vazyme. GAPDH was used as an internal reference, and the primer sequences for PCR are shown in Table 1.

Amplification was carried out under the following conditions: an initial denaturation step at 95°C for 60 seconds, followed by cycling conditions of denaturation at 95°C for 10 seconds, annealing at 60°C for 30 seconds, repeated for a total of 40 cycles. Melting curves were determined under the corresponding conditions. Each sample was subjected to triplicate experiments. The reference gene GAPDH was used for normalization. The relative expression levels of the target genes were calculated using the 2-ΔΔCt method.

Western Blot

Western Blot technique was employed to assess the protein expression levels of EIF4E, VEGF, and CCND1 in the treatment and control groups. Initially, cell samples collected using RIPA lysis buffer were lysed, and the total protein concentration was determined using the BCA assay kit (Shanghai Biyuntian Biotechnology, Product No.: P0012S). Based on the detected concentration, 20 μg of total protein was loaded per well. Electrophoresis was carried out using 5% stacking gel and 10% separating gel. Subsequently, the following primary antibodies were used for immune reactions: rabbit anti-human polyclonal antibody against phospho-EIF4E (Beijing Boao Sen Biotechnology, Product No.: bs-2446R, dilution 1:1000), mouse anti-human monoclonal antibody against EIF4E (Wuhan Sanying Biotechnology, Product No.: 66655-1-Ig, dilution 1:5000), mouse anti-human monoclonal antibody against VEGFA (Wuhan Sanying Biotechnology, Product No.: 66828-1-Ig, dilution 1:1000), mouse anti-human monoclonal antibody against CCND1 (Wuhan Sanying Biotechnology, Product No.: 60186-1-Ig, dilution 1:5000), and mouse anti-human monoclonal antibody against GAPDH (Shanghai Biyuntian Biotechnology, Product No.: AF0006, dilution 1:1000). Subsequently, secondary antibodies conjugated with horseradish peroxidase (Shanghai Biyuntian Biotechnology, Product No.: A0216, dilution 1:1000) were used for immune reactions. Finally, super-sensitive ECL chemiluminescence reagent (Shanghai Biyuntian Biotechnology, Product No.: P0018S) was employed for visualization, and the ChemiDocTM Imaging System (Bio-Rad Laboratories, USA) was used for image analysis.

Statistical Analysis

GraphPad software was used for statistical analysis. Data were presented as (x ± s) and analyzed using the t-test for quantitative data. Pearson correlation analysis was performed for assessing correlations. A significance level of P < 0.05 was considered statistically significant.

Results

3D Cell Culture of SKOV3 Cells and Inhibitory Effect of 4EGI-1 on Aggregation

In this experiment, SKOV3 cells were subjected to 3D cell culture, and the impact of the EIF4E inhibitor 4EGI-1 on ovarian cancer cell aggregation was investigated. As depicted in Figure 1, compared to the control group (Figure 1A), the diameter of the SKOV3 cell spheres significantly decreased in the treatment group (Figure 1B) when exposed to 4EGI-1 under identical culture conditions. This observation indicates that inhibiting EIF4E expression effectively suppresses tumor aggregation.

Expression and Correlation Analysis of VEGFA, CCND1, and EIF4E in Ovarian Cancer Samples

To investigate the expression of VEGFA, CCND1, and EIF4E in ovarian cancer, we utilized the GEPIA online analysis tool and employed the Pearson correlation analysis method to compare expression differences between tumor and normal groups. As depicted in Figures 2A-C, the results indicate significantly elevated expression levels of VEGFA, CCND1, and EIF4E in the tumor group compared to the normal control group. Notably, the expression differences of VEGFA and CCND1 were statistically significant (p < 0.05). Furthermore, the correlation analysis revealed a positive correlation between VEGFA and CCND1 with EIF4E (Figures 2D-E), and this correlation exhibited significant statistical differences (p < 0.001). These findings suggest a potential pivotal role of VEGFA, CCND1, and EIF4E in the initiation and progression of ovarian cancer, indicating the presence of intricate interrelationships among them.

EIF4E, VEGFA, and CCND1 mRNA Expression in SKOV3 Cells

To investigate the function of EIF4E in SKOV3 cells, we conducted RT-PCR experiments comparing EIF4E inhibition group with the control group. As illustrated in Figure 3, treatment with 4EGI-1 significantly reduced EIF4E expression (0.58±0.09 vs. control, p < 0.01). Concurrently, mRNA expression of VEGFA (0.76±0.15 vs. control, p < 0.05) and CCND1 (0.81±0.11 vs. control, p < 0.05) also displayed a substantial decrease. These findings underscore the significant impact of EIF4E inhibition on the expression of VEGFA and CCND1, indicating statistically significant differences.

Protein Expression Profiles in SKOV3 Cells with EIF4E Inhibition and Control Group

Protein expression of EIF4E, VEGFA, and CCND1 was assessed using Western Blot in the 4EGI-1 treatment group and the control group. As presented in Figure 4, the expression of p-EIF4E was significantly lower in the 4EGI-1 treatment group compared to the control group (0.33±0.14 vs. control, p < 0.001). Simultaneously, the expression of VEGFA (0.53±0.18 vs. control, p < 0.01) and CCND1 (0.44±0.16 vs. control, p < 0.001) in the 4EGI-1 treatment group exhibited a marked reduction compared to the control group.

Discussion

EIF4E is a post-transcriptional modification factor that plays a pivotal role in protein synthesis. Recent studies have underscored its critical involvement in various cancers [10]. In the context of ovarian cancer research, elevated EIF4E expression has been observed in late-stage ovarian cancer tissues, with low EIF4E expression correlating to higher survival rates [9]. Suppression of EIF4E expression or function has been shown to inhibit ovarian cancer cell proliferation, invasion, and promote apoptosis. Various compounds and drugs that inhibit EIF4E have been identified, rendering them potential candidates for ovarian cancer treatment [11]. Based on the progressing understanding of EIF4E's role in ovarian cancer, inhibiting EIF4E has emerged as a novel therapeutic avenue for the disease. 4EGI-1, a cap-dependent translation small molecule inhibitor, has been suggested to disrupt the formation of the eIF4E complex [12]. In this study, our analysis of public databases revealed elevated EIF4E expression in ovarian cancer patients compared to normal controls. Furthermore, through treatment with 4EGI-1 in the SKOV3 ovarian cancer cell line, we observed a capacity for 4EGI-1 to inhibit SKOV3 cell spheroid formation. Concurrently, results from PCR and Western Blot analyses demonstrated effective EIF4E inhibition by 4EGI-1. Collectively, 4EGI-1 effectively suppresses EIF4E expression and may exert its effects on ovarian cancer therapy by modulating EIF4E.

Vascular Endothelial Growth Factor (VEGF) is a protein that stimulates angiogenesis and increases vascular permeability, playing a crucial role in tumor growth and metastasis [13]. In ovarian cancer, excessive release of VEGF by tumor cells leads to increased angiogenesis, forming a new vascular network to provide nutrients and oxygen to tumor cells. The formation of new blood vessels enables tumor growth, proliferation, and facilitates tumor cell dissemination into the bloodstream, contributing to distant metastasis [14]. As a significant member of the VEGF family, VEGFA has been extensively studied, and it has been reported that VEGFA expression is notably higher in ovarian cancer tumors [15], consistent with our public database analysis. Furthermore, elevated EIF4E levels have been associated with increased malignant tumor VEGF mRNA translation [16]. Through the use of the EIF4E inhibitor 4EGI-1 in ovarian cancer cell lines, we observed a downregulation in both mRNA and protein expression levels of VEGFA. This suggests that EIF4E inhibition might affect ovarian cancer cell angiogenesis capability through downregulation of VEGF expression.

Cyclin D1 (CCND1) is a cell cycle regulatory protein that participates in controlling cell entry into the S phase and the cell division process. In ovarian cancer, overexpression of CCND1 is associated with increased tumor proliferation activity and poor prognosis [17]. Elevated CCND1 levels promote cell cycle progression, leading to uncontrolled cell proliferation [18]. Additionally, CCND1 can activate cell cycle-related signaling pathways, promoting cancer cell growth and invasion capabilities [19]. Studies have shown that CCND1 gene expression is significantly higher in ovarian cancer tissues compared to normal ovarian tissues [20], potentially promoting proliferation and cell cycle progression through enhanced cyclin D1 translation [9]. Our public database analysis results confirm these observations. Furthermore, treatment with the EIF4E inhibitor 4EGI-1 in ovarian cancer cell lines resulted in varying degrees of downregulation in CCND1 mRNA and protein levels. This indicates that EIF4E inhibition might affect ovarian cancer cell proliferation and cell cycle progression through regulation of CCND1 expression.

In conclusion, overexpression of EIF4E appears to be closely associated with the clinical and pathological characteristics of ovarian cancer patients. In various tumors, EIF4E is significantly correlated with VEGF and cyclin D1, suggesting its role in the regulation of protein translation related to angiogenesis and growth [9, 21]. The correlation analysis results in our study further confirmed the positive correlation among EIF4E, VEGFA, and CCND1 in ovarian cancer. Simultaneous inhibition of EIF4E also led to downregulation of VEGFA and CCND1 expression, validating their interconnectedness. Thus, targeted therapy against EIF4E may prove to be an effective strategy for treating ovarian cancer. However, further research and clinical trials are necessary to assess the safety and efficacy of targeted EIF4E therapy, offering more effective treatment options for ovarian cancer patients.

Acknowledgments:

Funding: This study was supported by the Joint Project of Southwest Medical University and the Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University (Grant No. 2020XYLH-043).

Conflict of Interest: The authors declare no conflicts of interest.

#Ovarian cancer #Eukaryotic translation initiation factor 4E #Vascular endothelial growth factor A #Cyclin D1 #Review Article in Journal of Clinical Case Reports Medical Images and Health Sciences .#jcrmhs

2 notes · View notes

jcmarchi · 9 months ago

Text

Innovative Chemotherapy Approach Shows Promise Against Lung Cancer - Technology Org

New Post has been published on https://thedigitalinsider.com/innovative-chemotherapy-approach-shows-promise-against-lung-cancer-technology-org/

Innovative Chemotherapy Approach Shows Promise Against Lung Cancer - Technology Org

Lung cancer is not the most common form of cancer, but it is by far the deadliest.

Kytai T. Nguyen, the Alfred R. and Janet H. Potvin Distinguished Professor in Bioengineering at UTA. Image credit: UTA

Despite treatments such as surgery, radiation therapy and chemotherapy, only about a quarter of all people with the disease will live more than five years after diagnosis, and lung cancer kills more than 1.8 million people worldwide each year, according to the World Health Organization.

To improve the odds for patients with lung cancer, researchers from The University of Texas at Arlington and UT Southwestern Medical Center have pioneered a novel approach to deliver cancer-killing drugs directly into cancer cells.

“Our method uses the patient’s own cellular material as a trojan horse to transport a targeted drug payload directly to the lung cancer cells,” said Kytai T. Nguyen, lead author of a new study on the technique in the peer-reviewed Bioactive Materials and the Alfred R. and Janet H. Potvin Distinguished Professor in Bioengineering at UTA. “The process involves isolating T-cells (a type of immune cell) from the cancer patient and modifying them to express a specific receptor that targets the cancer cells.”

The crucial step in this new technique involves isolating the cell membrane from these modified T-cells, loading the membranes with chemotherapy medications, and then coating them onto tiny drug-delivery granules. These nanoparticles are roughly 1/100 the size of a strand of hair.

Jon Weidanz, associate vice president for research and innovation and professor of kinesiology and bioengineering. Image credit: UTA

When these membrane-coated nanoparticles are injected back into the patient, the cell membrane acts as a guide, directing the nanoparticles to the tumor cells with precision. This approach is designed to deceive the patient’s immune system, as the coated nanoparticles mimic the properties of immune cells, avoiding detection and clearance by the body.

“The key advantage of this method lies in its highly targeted nature, which allows it to overcome the limitations of conventional chemotherapy that often lead to detrimental side effects and reduced quality of life for patients,” said co-author Jon Weidanz, associate vice president for research and innovation and a researcher in kinesiology and bioengineering.

“By delivering chemotherapy directly to the tumor cells, the system aims to minimize collateral damage to healthy tissues,” continued Weidanz, who also is a member of UTA’s Multi-Interprofessional Center for Health Informatics.

In the study, researchers loaded the nanoparticles with the anti-cancer drug Cisplatin. The membrane-coated nanoparticles accumulated in parts of the body with the tumors rather than in other parts of the body. As a result, this targeted delivery system reduced the size of the tumors in the control group, demonstrating its efficacy.

“This personalized approach could pave the way for a new era of medicine tailored to each patient’s unique characteristics and the specific nature of their tumor,” Nguyen said. “The potential for reduced side effects and improved effectiveness makes our technique a noteworthy advancement in the field of cancer treatment.”

Source: University of Texas at Arlington

You can offer your link to a page which is relevant to the topic of this post.

2 notes · View notes

medchemexpressinhibitor-blog · 11 months ago

Text

Exploring the Potential of a Glutamine Transporter Inhibitor

Introduction

Cancer cells exhibit distinct metabolic characteristics, and targeting specific metabolic pathways has become an area of intense research in cancer therapeutics. JPH203, a glutamine transporter inhibitor, has emerged as a promising drug candidate for disrupting the metabolic processes crucial to cancer cell survival and proliferation. This article aims to explore factual evidence regarding the efficacy and potential applications of JPH203.

Understanding JPH203

JPH203 is a selective inhibitor of the glutamine transporter ASCT2 (alanine, serine, cysteine-preferring transporter 2). ASCT2 plays a critical role in transporting glutamine, an amino acid essential for cancer cell growth and survival[¹^]. By targeting ASCT2, JPH203 aims to disrupt glutamine uptake and subsequently alter cancer cell metabolism.

The Mechanism of Action

Inhibition of Glutamine Uptake: JPH203 binds to ASCT2, preventing the transport of extracellular glutamine into cancer cells. This disruption hampers the availability of glutamine, an essential nutrient for cancer cell metabolism, thereby impairing their growth and survival[²^].

Factual Evidence Supporting JPH203

Preclinical Studies: Initial preclinical studies have demonstrated the efficacy of JPH203 in inhibiting cancer cell growth across various types of cancers, including lung, breast, pancreatic, and colorectal cancers[³^][⁴^]. These studies have shown that JPH203 treatment led to reduced glutamine uptake, impaired cell proliferation, and increased cell death.

Combination Therapy: JPH203 has been investigated in combination with other anticancer agents, such as chemotherapeutic drugs and targeted therapies. Preclinical studies have suggested synergistic effects when JPH203 is used in combination with other treatments, leading to enhanced anticancer activity[⁵^][⁶^]. These findings highlight the potential of JPH203 as an adjunct therapy to improve treatment outcomes.

Metabolic Reprogramming: Glutamine is a crucial nutrient for cancer cells, serving as a building block for macromolecules and as a source of energy. By inhibiting glutamine uptake, JPH203 disrupts cancer cell metabolism. This metabolic reprogramming can render cancer cells more susceptible to other therapies and potentially overcome drug resistance[⁷^].

Clinical Development

JPH203 is currently undergoing clinical trials to evaluate its safety, tolerability, and efficacy in patients with advanced solid tumors. These studies aim to determine the optimal dosage, treatment duration, and potential side effects to further establish the therapeutic potential of JPH203 in clinical settings[⁸^].

Conclusion

JPH203, a selective inhibitor of the glutamine transporter ASCT2, shows promise as a targeted approach to disrupt cancer cell metabolism. Preclinical studies have demonstrated its ability to inhibit glutamine uptake, impair cancer cell growth, and enhance cell death. The ongoing clinical trials will provide valuable insights into the safety and efficacy of JPH203 in human patients and its potential as part of combination therapies.

While JPH203 holds significant potential as a novel anticancer agent, further research is needed to fully understand its mechanisms of action, optimize treatment strategies, and identify the patient populations that may benefit most from its use. The development of JPH203 represents an exciting advancement in the quest for more effective and targeted cancer therapeutics.please visit MedChemExpress

(Note: This article is for informational purposes only and should not replace professional medical advice. Always consult your healthcare provider for personalized treatment recommendations.)

#biochemistry #business #chemistry #marketing

3 notes · View notes

justsomeoneintoomanyfandoms · 1 year ago

Note

HIIII I see that u hv a match up goin on and Id like to try! Would u mind doing one for me with Obey Me?

Pronouns : She/they

Sexuality: Im not sure exactly??... still discovering but I know that I like both sexes

Infp 4w5 / Cancer sun Taurus moon n Scorpio rising (I saw some doing not just the sun sign so i think it would be fun if i include all 3 lol)

Appearance: Im South East Asian. Around 5'2. I hv shoulder length black hair, black eyes and olive toned skin. My hairstyle is akin to the jellyfish hair. I rarely wear makeup and would just hv my bare face out due to its sensitivity to breakouts. And my clothing, its mostly modest/covering for academic places or just comfy and quick with any cool baggy tees i hv. Its my current closet, since i dont hv much occasions to go grand and i just wanna blend in with everyone around me lookin like an npc. But id love to wear more self expressing stuff in the future, to my desire. More accessories, colorful makeups and fashions like dark couquette/gyaru or so!

Personality: My personality, id say its two sided. I guess hv an open mind and easy going (to some degree ofc). A dream chaser and a listener. Sometimes (just sometimes), i can get my mind through a problem and stay grounded. Im also empathic? I like consoling with people and I appreciate the smallest details. I feel for people's struggle and I hold hopes in them. However, i can get moody, its so unexpected and intense that even im scared of it. I can be very quiet then, and dissociative. Id just want to be alone by that time to figure out my situation. Ive been said to appear gloomy or hard to approach too :cry: If im pissed, im venomous. And im actually an anxious person, of all sorts of things. Self deprecating too, i almost forgot abt that. But if i feel suitable, i get funky and enjoy myself hehe.

Likes/Dislikes : I like visual novels, rhythm games and those with good storytelling; a variety of music genres that focus on melody, instrument, composing; local asian food; sleeping with plushies; arts n crafts; esoteric things; philosophy study; my friends; solitude and continuation; aesthetic or hidden values and uhhh nice, mannered intriguing people.

I dont like smelly people doe. People who are narrow minded icks me oops. Pls dont tryna barge in on me when im busy unless it helps. I hate the sun... And not getting myself tented after a long day. I dislike my parents as well, yikes. Worst of all, being opressed.

Hobbies : doll, bracelet making; drawing, online shopping, rhythm game arcade, reading philosophy works, uhh getting invested in random medias...

Anyways, thats my submission! If u do reply, tysm for the matchup!!!

Hi Anon! Thank you for the request! I hope you like your matchup!

In Obey Me, I match you with...

Asmo is the best person to hype you up about wearing more self-expressing things. He’s great at putting outfits together and will give you honest and genuine feedback.

Doesn’t mind your personality changes. He knows what mood swings are like so he’s very understanding.

Please go online shopping with him! But set a budget because you’re both liable to get caught up in the energy and spend too much. But online shopping with Asmo would be so much fun.

Not great at giving you alone time but if you say you need some space, he’ll respect your wishes. While you’re enjoying your alone time, he’ll do a spa day or hang out with some of his friends.

Asmo loves your plushies. He thinks they’re really cute and, if you’re okay with it, would love to borrow some of them to sleep with as well. He’ll take good care of them and swaps them out occasionally so you’ve got a constantly rotating roster of plushies in your room.

#writing #fanfic #matchup #matchup request #request #obey me #obey me shall we date #obey me nightbringer #asmodeus

4 notes · View notes

ariel-seagull-wings · 2 years ago

Text

JANINE AND EGON'S WEDDING QUESTIONS (MOVIE, NOVELIZATION AND COMICS VERSE)

@spengnitzed @bixiebeet @professorlehnsherr-almashy @angelixgutz

Imagine what music they'd have? What food? Would it be outside? What kind of theme, if any, would they have?

Jazz and jewish folk music. The ceremony would be outside in the garden, while the dinner reception, with Ashkenazi jewish food from Poland, Russia and Ukraine and the dancing party would be inside the house of their friend, Ray. The theme would be woodlands and mycology.

Who would they invite?

Ray (who is Egon's best man and provider of the house where the wedding is celebrated), Winston, Peter, Dana, Egon's mother, brother, sister-in-law and baby nephew, Janine's parents, sister, grandmother and maternal uncles and cousins.

What season is it? Day or night? What colors do people wear?

Autumn, evening till night, starting at 15:00 pm. While the decoration is green and brown, the guests are left free to choose the colors of their clothes.

Is it traditional or do they do something wild?

The ceremony follows traditional jewish marriage rituals, along with including a justice of peace to assist the civil legalization and documentation of the wedding.

Did they write their own vows? Who is the priest/priestess/minister marrying you? Or is it a family member or other platonic F/O?

They do write their own vows, taking some inspiration from literature. Janine's family rabbi and a paid justice of peace marries her and Egon.

Are they wearing suits? Dresses? Something else entirely?

Janine wears a tea-length dress with a lace top and puffy skirt.

Egon wears a black suit and bowtie.

What is their cake like if they have one?

Is a cake decorated with candy mushrooms and sugar leafs, topped with two snails representing the couple.

Do they throw the bouquet for someone to catch or do they pass out one flower to everyone so they let everyone know they are worthy of love?

Janine appears like she will throw one bouquet to one person, then surprises everyone when the flowers are untied and everybody catches a flower.

Do they have a party afterwards? What music?

A dancing party with the music of Cleo Laine, Harry Belafonte, Ofra Haza and The Parvarim.

What is their honeymoon like? Is it a stay at home one? Do they go somewhere exciting? How long is their trip?

A three week vacation to San Diego, California.

How many kids do they have? What are their names?

Three kids: Noemi, Tobin and Batya.

NICKNAME(S): Baby Smurf, Sugar Plum.

FACECLAIM: Violet Ramis (child), Jenny Slate (adult).

BIRTH: August 25th 1984.

ZODIAC SIGN: Virgo.

SEXUALITY: Bissexual.

GENDER: Female.

ORIGIN: Forest Hills, Queens, New York City.

NATIONALITY: US American.

CHARACTERISTICS:

+ Curious, inquisitive, creative, extroverted, with a fascination for gallows humor;

+ Loves colorful clothes, cartoons and comic books;

+ Has a strong temper and rarely disguises when she has either contempt or desire to kill someone she perceives as an enemy;

WEAPON OF CHOICE:

+ P.K.E Meter

+ Proton Pack

+ Ghost Trap

OTHER PERSONAL INFO:

+ While she inherited the academic talent of her father, she has the more outgoing and bold approach to social interactions of her mother;

+ Considers the other Ghostbusters her uncles, with Ray and Winston being her favorites;

+ Is a huge fan of the Smurfs and Asterix comics and cartoons and a cosplayer;

+ Before deciding to pursue a career in STEM and Parapsychology, for a while she considered taking religious studies to become a rabbi. While she didn't went through with that, she still became and expert in Jewish Mythology and Folklore;

+ Besides being a Ghostbuster, Noemi also teaches about the paranormal at Columbia University.

NICKNAME(S): Bean Bunny.

FACECLAIM: Anton Yelchin (child and adult).

BIRTH: June 23th 1989.

ZODIAC SIGN: Cancer.

SEXUALITY: Asexual.

GENDER: Male.

ORIGIN: Forest Hills, Queens, New York City.

NATIONALITY: US American.

CHARACTERISTICS:

+ Calm, caring, empathetic, studious, who enjoys safety and tranquility;

+ Loves cooking, gardening and drawing;

+ Is anxious and gets stuck in a place when frightened;

WEAPON OF CHOICE:

+ P.K.E Meter

+ Ghost Trap

OTHER PERSONAL INFO:

+ Has the more quiet temperament of his father, and the belief in intuition from his mother, wich is formative of his view of science mainly as an instrument of nurturing;

+ Collects mold, spores and fungus, and also enjoys botanics, specially harvesting the mushrooms, fruits and vegetables to use in dishes he cooks for his friends and family;

+ Loves the Pogo comic strips, Fraggle Rock and the Dave the Gnome cartoon;

+ Studies to become a Landscape Architect, Environmental Engineer and Manager;

+ When reluctantly involved in Ghostbusting by his older sister, he only uses the P.K.E Meter and the Ghost Trap, seeing these instruments as something to try to communicate with the ghosts and help them get shelter and defend humans from harm, but he doesn’t handle the Proton Pack because is heavy and because he sees it as a intimidating gun.

NICKNAME(S): Ladybug.

FACECLAIM: Flora Guiet (child), Alexandra Socha (adult).

BIRTH: September 29th 1991.

ZODIAC SIGN: Libra.

SEXUALITY: Biromantic and demisexual.

GENDER: Female.

ORIGIN: Forest Hills, Queens, New York City.

NATIONALITY: US American.

CHARACTERISTICS:

+ Likes to keep things well organized to facilitate the work and everyday life of other people;

+ Physically agile;

+ In a conversation, can see connections between topics that the other person listening her would never imagine being related;

WEAPON OF CHOICE:

+Walkie-talkie

+Proton Pack

+Ghost Trap

+ Ecto Goggles

OTHER PERSONAL INFO:

+ Inherited her mother’s taste for racquetball, and also plays tennis;

+ Loves RPG, be they tabletop or video games, eventually getting a Masters Degree in Game Theory and Game Design;

+ Is fascinated with prehistoric animals, studying History, Biology, Zoology, Archeology and Paleontology, the area where she intends to become a Doctor;

+ Also enjoys photography;

+ Is a mix between a Explorer Historian, whose greatest pleasure is delving into the new world that they are exploring in search of knowledge as the greatest reward, and a Socializer Strategist, happy to collaborate in order to achieve bigger and better things than she could on her own, while having no problems assuming leadership if it means keeping the group safe and sound when the situation becomes especially dangerous.

Where do they live?

In an old two storey boarding house in Forest Hills, Queens, chosen because it looked similar to a drawing that Janine made in her childhood of her dream house, which should be old and covered with vines like the house that served as Madeline's boarding school.

#tumblr mutuals #fandom musings #ghostbusters 1984 #egon spengler #janine melnitz #harold ramis #annie potts #janegon #spengnitz #egonine

5 notes · View notes

screenshots123 · 1 year ago

Text

📅 Aug 2023 📰 New mRNA-based malaria vaccine shows promise in preclinical trials 🗞 News-Medical.net

The focus of the collaborative research investigating a novel target for malaria was originally on peptide-based vaccines. However, in 2018, the team shifted their approach and started investigating RNA-based vaccines – a decision that, so far, seems to have paid off with the recent success of RNA technology in vaccine development.

"While our successful peptide-based vaccines targeting malaria only contain small protein fragments of a malaria protein, mRNA vaccines encode an entire malaria protein," says the University of Melbourne's Dr Lauren Holz, Research Officer at the Doherty Institute and co-author of the paper.

To pack an extra protective punch, the mRNA vaccine has been combined with an adjuvant – originally developed at the Malaghan and Ferrier Institutes for cancer immunotherapies – which targets and stimulates liver-specific immune cells. This additional ingredient helps localise the RNA vaccine response to the liver, a key site in preventing the parasite from developing and maturing in the body.

"When the parasite first enters the bloodstream, it travels to the liver where it develops and matures before going on to infect blood cells, which is when disease symptoms occur," says Dr Mitch Ganley, Postdoctoral Research Fellow at the Ferrier Research Institute, and co-author of the study.

"Unlike the COVID-19 vaccine that works by neutralizing antibodies, our unique approach relies on T-cells which play a critical role in immunity. Specifically, a type of T-cell called a tissue-resident memory T-cell, that halts malaria infection in the liver to completely stop the spread of infection."

Dr Holz says the key advantage of this vaccine is that it isn't affected by previous exposure to malaria.

"A lot of malaria vaccines undergoing trials have worked really well in animal models or when they're given to people who haven't had malaria before, but they don't work well when given to people living in malaria-endemic regions. In contrast, our vaccine is still capable of generating protective liver-specific immune cells and providing protection even when the animal models have been pre-exposed to the disease," says Dr Holz.

2 notes · View notes

octalsoft · 16 hours ago

Text

The Role of Data Analytics in Clinical Trial Design and Analysis

What function does data analysis play in clinical trials? Can R and other technologies be used to improve clinical trial data analysis? Is it possible to use big data analysis in clinical trials? Experts would undoubtedly answer yes to all of these questions.

Clinical trials have changed dramatically in the recent decade, with significant new advances in immunotherapy, stem cell research, genomics, and cancer therapy, to name a few. Simultaneously, there has been a shift in the implementation of clinical trials as well as the process of discovering and producing required medications.

Researchers acquire faster insights through the review of databases of real-world patient information and the production of synthetic control arms, to name a few instances of the expanding demand for clinical trial data analysis.

In this instance, they can also assess medication performance after regulatory approval. This has reduced the expense and time associated with studies, while also reducing the total burden on patients and allowing for shorter medication go-to-market timetables.

What is driving data analysis in clinical trials?

AI (artificial intelligence) and ML (machine learning) are driving clinical trial data analysis, allowing for the gathering, analysis, and creation of insights from huge volumes of real-time data at scale, which is far quicker than manual techniques.

The analysis and processing of medical imaging data for clinical trials, as well as data from other sources, is allowing process innovation while also aiding the discovery processes in terms of speeding up trials, go-to-market methods, and launches.

Data volumes have skyrocketed in recent years, thanks to greater wearable usage, genomic and genetic understanding of individuals, proteomic and metabolomic profiles, and complete clinical histories obtained from electronic health records.

According to reports, the global healthcare business generates 30% of the world's data volumes. The CAGR (compound annual growth rate) for healthcare data will also reach 36% by 2025. From 2016 to 2020, the volume of patient data in healthcare systems has increased by a stunning 500%.

Data analysis in clinical trials- What else should you note?

Here are a few factors that are worth noting:

AI-based solutions have been able to use massive amounts of data while curating and storing it in non-standard forms. Machine learning enables the detection of data patterns in the absence of any prior preconceptions.

New AI technologies are likely to have a significant impact on medication research and clinical trials. According to Morgan Stanley Research, the use of ML and AI might result in 50 additional novel cures over the next ten years, turning into a market worth more than $50 billion. ML is already being used in conjunction with statistical analysis to glean insights from massive real-world data warehouses and clinical histories.

Clinical trial design software and data modeling approaches are already being employed extensively, from discovering laboratory indicators for forecasting the possibility of complicated syndromes in patients of various categories to researching and comprehending clinical risk aspects.

Life sciences organizations are utilizing AI technologies to ensure that clinical trials generate regulatory-quality data, as well as classifying and sorting information entry issues, inconsistencies, outliers, and other misreported but adverse effects in order to expedite drug approval procedures.

Synthetic control arm development

When considering the creation of synthetic control arms, the relevance of data analysis in clinical trials becomes further clearer. Clinical drug research and testing might be accelerated while improving success rates and clinical trial designs.

Synthetic control arms may aid in overcoming patient classification issues and shortening the time necessary for medical therapy development. It may also improve patient recruitment by alleviating worries about receiving placebos and allowing for better administration of varied and large-scale trials.

Synthetic control arms use both historical clinical trials and real-world data to mimic patient control groups, eliminating the need for patients to receive placebo treatments that may be harmful to their health. It may have a detrimental influence on patient outcomes and trial enrollment.

The strategy may be more effective for uncommon diseases with smaller patient populations and shorter lifespans due to the disease's aggressive nature. Using such technologies for clinical trials and bringing them closer to end-patients may considerably reduce the overall hassles of going to research locations/sites, as well as the issue of consistent testing.

ML and AI for better discovery of drugs

For physicians, ML and AI may enable faster analysis of data sets obtained earlier and at a faster rate, resulting in improved reliability and efficiency. The incorporation of artificial intelligence in clinical trial design for synthetic control arms into conventional research will open up new avenues for medication development transformation.

As the number of data sources increases, such as health apps, personal wearables and other devices, electronic medical records, and other patient data, these may become the safest and quickest mechanisms for tapping real-world data for better research into ailments with large patient populations.

Researchers may attain larger, more homogeneous patient groups while still gaining critical insights. Here are some other items to consider:

ML and AI tools may aid in the discovery of crucial insights that would otherwise take a large number of hours for humans. They can produce findings in a matter of minutes.

Larger pharmaceutical companies may have several active studies with multiple databases. There is a greater requirement for efficient data analysis and management when there are several data points. Otherwise, data mismanagement might lead to costly blunders.

These tools may be used by researchers to quickly discover crucial trends and potential trial-related issues in real-time.

In Summation

Data analysis allows for the prediction of clinical trial outcomes for novel drugs. All stakeholders benefit from faster and more precise results/predictions, as well as superior risk and reward estimates.

Researchers may construct clinical trials more successfully with improved visibility into drug development risks, broadening patient selection criteria and quickly sorting through numerous aspects at the same time.

Data analytics is allowing for better decision-making throughout the drug development process, while also improving overall clinical trial efficiency through predictive modeling, discovering new possible candidate molecules for effective medication development with more confidence.

Companies may give real-time reactions to clinical data insights via automation and big data, while also generating more efficient trials and significantly reducing trial duration.

Clinical trial outcomes are important performance indicators, at least in the eyes of firms and investors. They are also the start of cooperation between patients, groups, and the broader healthcare industry. As a result of the aforementioned factors, there is an obvious demand for big data analysis in clinical trials.

#data analysis #data analytics #clinical data management

0 notes

crimsonpublisherscancerstudy · 3 months ago

Text

Unstipulated and InexactIndeterminate Dendritic Cell Tumour_Crimson Publishers

Opinion

Indeterminate dendritic cell tumour emerges as an extremely exceptional tumefaction composed of proliferation of dendritic cells or cells of histiocytic lineage. Additionally designated as indeterminate cell histiocytosis, indeterminate cell tumour or indeterminate dendritic cell tumour, true cutaneous dendritic cell tumour may depict solitary or multifocal lesions. Generally, tumefaction is confined to diverse cutaneous surfaces wherein deep seated visceral or regional lymph node involvement is exceptional. Tumour forming indeterminate cells simulate Langerhans cells vis-à-vis morphological and antigenic features. However, indeterminate cells appear devoid of Birbeck granules and lack immune reactivity to langerin (CD207). Median age of disease emergence is 45 years although no age of disease occurrence is exempt. An almost equivalent gender predilection is encountered. Indeterminate dendritic cell tumour predominantly(~88%) implicates diverse cutaneous surfaces. Infrequently, regional lymph nodes (9%) or spleen (2.3%) may be involved [1,2]. Of obscure a etiology, neoplasm expounds varied concurrence between indeterminate cells and Langerhans cells as ~indeterminate cells manifest as Langerhans cells devoid of Birbeck granules ~indeterminate cells represent as immature Langerhans cells. A subset of neoplasms express dendritic cell marker ZBTB46, thereby indicating the emergence of neoplasms directly from bone marrow progenitors, in contrast to embryonic precursors which undergo localized cutaneous regeneration [1,2].

Read more about this article:

For more articles in Novel Approaches in Cancer Study

#cancer #breast cancer #crimson cancer #crimson publishers #novel approaches in cancer study #open access journal #crimson nacs

1 note · View note

delveinsight12 · 3 days ago

Text

SLAMF7 Inhibitors Market Size, Target Population, Competitive Landscape, and Forecast to 2034

The SLAMF7 inhibitors market represents a growing segment in immuno-oncology, particularly for hematological malignancies. As therapies targeting SLAMF7 (Signaling Lymphocytic Activation Molecule Family Member 7) continue to evolve, their market potential is increasingly recognized. This article explores the current and future outlook of the SLAMF7 inhibitors market, focusing on its size, target population, competitive landscape, and market trends through 2034.

SLAMF7 Inhibitors Market Size and Growth Dynamics

The SLAMF7 inhibitors market is expected to expand significantly by 2034, driven by the increasing prevalence of cancers such as multiple myeloma and rising adoption of targeted therapies. The global demand for novel, effective treatments is steering investments in research and development, which is also supported by government initiatives and partnerships between academia and the pharmaceutical industry.

Key SLAMF7 Inhibitors market growth drivers include:

- Rising Incidence of Multiple Myeloma: Multiple myeloma remains one of the primary indications for SLAMF7-targeting therapies. As incidence rates climb globally, so does the demand for targeted treatment options.

- Adoption of Immunotherapies: Immunotherapy is becoming a cornerstone in cancer treatment, with SLAMF7 inhibitors offering a promising approach by enhancing immune response against malignant cells.

- Expanding Application Areas: Beyond multiple myeloma, research is exploring the potential of SLAMF7 inhibitors in other cancers and autoimmune conditions, which could further boost market growth.

Regions such as North America and Europe dominate the market due to advanced healthcare infrastructure and early adoption of innovative therapies. However, the Asia-Pacific region is anticipated to see the fastest growth, spurred by improving healthcare systems and increasing awareness of targeted cancer treatments.

Request for a sample report @ https://www.delveinsight.com/sample-request/slamf7-inhibitors-market-forecast

SLAMF7 Inhibitors Target Population

SLAMF7 inhibitors primarily target patients with:

- Multiple Myeloma: SLAMF7 is highly expressed in myeloma cells, making it an effective target for therapies.

- Other Hematological Malignancies: Research is ongoing into their use for treating lymphomas and leukemias.

- Potential Non-Cancer Indications: Studies suggest potential in autoimmune diseases, further broadening the addressable patient population.

With an aging global population and improved diagnostic capabilities, the target pool for SLAMF7 inhibitors is likely to grow, presenting significant opportunities for market expansion.

SLAMF7 Inhibitors Competitive Landscape

The SLAMF7 inhibitors market is competitive, with several pharmaceutical giants and biotech firms actively engaged in the development and commercialization of these therapies. The competitive dynamics are defined by innovations in combination therapies, improved drug delivery mechanisms, and expansion into broader therapeutic areas.

Download sample report @ https://www.delveinsight.com/sample-request/slamf7-inhibitors-market-forecast

Key SLAMF7 Inhibitors Companies and Products

- Bristol Myers Squibb (Empliciti - Elotuzumab): As a pioneering SLAMF7-targeting therapy approved for multiple myeloma, Empliciti remains a cornerstone product. Its clinical success underscores the therapeutic value of SLAMF7 inhibitors.

- Emerging Biotechs: Smaller companies are also contributing to innovation in this space, with a focus on enhancing drug efficacy and patient outcomes through next-generation SLAMF7 inhibitors.

SLAMF7 Inhibitors Research and Development Trends

- Combination Therapies: SLAMF7 inhibitors are increasingly being used in combination with other immunomodulators or checkpoint inhibitors to improve treatment efficacy.

- Pipeline Developments: A robust pipeline of SLAMF7-targeting drugs reflects ongoing efforts to expand indications and overcome resistance mechanisms in cancer cells.

SLAMF7 Inhibitors Technological Advancements and Innovations

The SLAMF7 inhibitors market benefits from advancements in biotechnology and precision medicine:

- Enhanced Antibody Engineering: The development of bispecific antibodies targeting SLAMF7 and other immune receptors is a significant area of focus.

- Biomarker Identification: Precision medicine approaches are leveraging biomarkers to identify patients most likely to benefit from SLAMF7 therapies.

- Improvements in Drug Delivery: Innovations in delivery systems aim to reduce dosing frequency and improve patient compliance.

These advancements not only enhance therapeutic outcomes but also improve the accessibility and affordability of these treatments.

SLAMF7 Inhibitors Market Challenges

Despite its promise, the SLAMF7 inhibitors market faces several challenges:

1. High Development Costs: R&D for immuno-oncology therapies is resource-intensive, which impacts pricing and market penetration.

2. Therapeutic Resistance: The development of resistance to SLAMF7-targeting therapies requires continuous innovation to maintain efficacy.

3. Limited Awareness in Emerging Markets: While awareness is growing, it remains a barrier in regions with underdeveloped healthcare infrastructure.

Efforts to address these issues include collaboration between industry stakeholders, patient advocacy, and initiatives to improve access in low- and middle-income countries.

SLAMF7 Inhibitors Market Forecast to 2034

The SLAMF7 inhibitors market is projected to grow at a robust compound annual growth rate (CAGR) through 2034. Key growth drivers include:

- Expanding Indications: The use of SLAMF7 inhibitors in non-oncological conditions could significantly expand the market.

- Strategic Collaborations: Partnerships between pharmaceutical companies and research institutions are expected to accelerate innovation and market entry.

- Regulatory Approvals: Anticipated approvals of pipeline drugs will add to the therapeutic arsenal and drive market growth.

While North America and Europe will continue to lead in terms of market share, Asia-Pacific is poised to emerge as a significant player due to its rapidly evolving healthcare landscape.

The SLAMF7 inhibitors market is on a trajectory of rapid growth, fueled by its proven efficacy in managing hematological malignancies and its expanding role in immunotherapy. Innovations in drug development, coupled with efforts to address challenges such as cost and access, will be critical in unlocking the market's full potential.

For a deeper dive into the SLAMF7 inhibitors market, including detailed insights into its competitive landscape and future trends, visit the [DelveInsight SLAMF7 Inhibitors Market Forecast Report](https://www.delveinsight.com/report-store/slamf7-inhibitors-market-forecast).

0 notes

jcmarchi · 11 months ago

Text

Engineers develop a vibrating, ingestible capsule that might help treat obesity

New Post has been published on https://thedigitalinsider.com/engineers-develop-a-vibrating-ingestible-capsule-that-might-help-treat-obesity/

Engineers develop a vibrating, ingestible capsule that might help treat obesity

When you eat a large meal, your stomach sends signals to your brain that create a feeling of fullness, which helps you realize it’s time to stop eating. A stomach full of liquid can also send these messages, which is why dieters are often advised to drink a glass of water before eating.

MIT engineers have now come up with a new way to take advantage of that phenomenon, using an ingestible capsule that vibrates within the stomach. These vibrations activate the same stretch receptors that sense when the stomach is distended, creating an illusory sense of fullness.

In animals who were given this pill 20 minutes before eating, the researchers found that this treatment not only stimulated the release of hormones that signal satiety, but also reduced the animals’ food intake by about 40 percent. Scientists have much more to learn about the mechanisms that influence human body weight, but if further research suggests this technology could be safely used in humans, such a pill might offer a minimally invasive way to treat obesity, the researchers say.

“For somebody who wants to lose weight or control their appetite, it could be taken before each meal,” says Shriya Srinivasan PhD ’20, a former MIT graduate student and postdoc who is now an assistant professor of bioengineering at Harvard University. “This could be really interesting in that it would provide an option that could minimize the side effects that we see with the other pharmacological treatments out there.”

Srinivasan is the lead author of the new study, which appears today in Science Advances. Giovanni Traverso, an associate professor of mechanical engineering at MIT and a gastroenterologist at Brigham and Women’s Hospital, is the senior author of the paper.

A sense of fullness

When the stomach becomes distended, specialized cells called mechanoreceptors sense that stretching and send signals to the brain via the vagus nerve. As a result, the brain stimulates production of insulin, as well as hormones such as C-peptide, Pyy, and GLP-1. All of these hormones work together to help people digest their food, feel full, and stop eating. At the same time, levels of ghrelin, a hunger-promoting hormone, go down.

While a graduate student at MIT, Srinivasan became interested in the idea of controlling this process by artificially stretching the mechanoreceptors that line the stomach, through vibration. Previous research had shown that vibration applied to a muscle can induce a sense that the muscle has stretched farther than it actually has.

“I wondered if we could activate stretch receptors in the stomach by vibrating them and having them perceive that the entire stomach has been expanded, to create an illusory sense of distension that could modulate hormones and eating patterns,” Srinivasan says.

As a postdoc in MIT’s Koch Institute for Integrative Cancer Research, Srinivasan worked closely with Traverso’s lab, which has developed many novel approaches to oral delivery of drugs and electronic devices. For this study, Srinivasan, Traverso, and a team of researchers designed a capsule about the size of a multivitamin, that includes a vibrating element. When the pill, which is powered by a small silver oxide battery, reaches the stomach, acidic gastric fluids dissolve a gelatinous membrane that covers the capsule, completing the electronic circuit that activates the vibrating motor.

In a study in animals, the researchers showed that once the pill begins vibrating, it activates mechanoreceptors, which send signals to the brain through stimulation of the vagus nerve. The researchers tracked hormone levels during the periods when the device was vibrating and found that they mirrored the hormone release patterns seen following a meal, even when the animals had fasted.

The researchers then tested the effects of this stimulation on the animals’ appetite. They found that when the pill was activated for about 20 minutes, before the animals were offered food, they consumed 40 percent less, on average, than they did when the pill was not activated. The animals also gained weight more slowly during periods when they were treated with the vibrating pill.

“The behavioral change is profound, and that’s using the endogenous system rather than any exogenous therapeutic. We have the potential to overcome some of the challenges and costs associated with delivery of biologic drugs by modulating the enteric nervous system,” Traverso says.

The current version of the pill is designed to vibrate for about 30 minutes after arriving in the stomach, but the researchers plan to explore the possibility of adapting it to remain in the stomach for longer periods of time, where it could be turned on and off wirelessly as needed. In the animal studies, the pills passed through the digestive tract within four or five days.

The study also found that the animals did not show any signs of obstruction, perforation, or other negative impacts while the pill was in their digestive tract.

An alternative approach

This type of pill could offer an alternative to the current approaches to treating obesity, the researchers say. Nonmedical interventions such as diet exercise don’t always work, and many of the existing medical interventions are fairly invasive. These include gastric bypass surgery, as well as gastric balloons, which are no longer used widely in the United States due to safety concerns.

Drugs such as GLP-1 agonists can also aid weight loss, but most of them have to be injected, and they are unaffordable for many people. According to Srinivasan, the MIT capsules could be manufactured at a cost that would make them available to people who don’t have access to more expensive treatment options.

“For a lot of populations, some of the more effective therapies for obesity are very costly. At scale, our device could be manufactured at a pretty cost-effective price point,” she says. “I’d love to see how this would transform care and therapy for people in global health settings who may not have access to some of the more sophisticated or expensive options that are available today.”

The researchers now plan to explore ways to scale up the manufacturing of the capsules, which could enable clinical trials in humans. Such studies would be important to learn more about the devices’ safety, as well as determine the best time to swallow the capsule before to a meal and how often it would need to be administered.

Other authors of the paper include Amro Alshareef, Alexandria Hwang, Ceara Byrne, Johannes Kuosmann, Keiko Ishida, Joshua Jenkins, Sabrina Liu, Wiam Abdalla Mohammed Madani, Alison Hayward, and Niora Fabian.

The research was funded by the National Institutes of Health, Novo Nordisk, the Department of Mechanical Engineering at MIT, a Schmidt Science Fellowship, and the National Science Foundation.

1 note · View note

bbmct · 3 days ago

Text

BBMCT: Set Up New Medical Research at AIIMS Hospital

## Enhances Patient Care and Outcomes

## Accelerates the Progress of Innovations

## Establishes Partnerships with Leading Institutions

## Fills Significant Gaps in Knowledge

## Secures Funding for Research Projects

## Improves the Institution’s Academic Reputation

## Promotes Collaboration Among Research Teams

## Supports Advancements Based on Evidence

/media/fe48b75114c4a7ccf24b7775c9477286

— -

### FAQs About BBMCT and Its Role at AIIMS Hospital

**1. What is BBMCT’s role at AIIMS Hospital?**

**2. How does BBMCT improve patient outcomes?**

**3. What innovations does BBMCT support at AIIMS?**

**4. How does BBMCT help AIIMS secure research funding?**

**5. How do BBMCT’s partnerships benefit AIIMS Hospital?**

— -

### Conclusion

Subscribe to BBMCLINICALTRIALS YouTube channel for Research Insights

#anya mouthwashing #artists on tumblr #batman #bucktommy #captain curly #cats of tumblr #agatha harkness #agatha all along #911 abc #dan and phil

1 note · View note

stevenwilliam12 · 3 days ago

Text

Non-metastatic Prostate Cancer (nmPC) Market Insight and Forecast: Trends Leading to 2034

Introduction

Non-metastatic prostate cancer (nmPC) refers to localized or regionally confined prostate cancer that has not yet spread to distant organs. The management of nmPC focuses on delaying disease progression, preserving quality of life, and preventing metastasis. The Non-metastatic Prostate Cancer (nmPC) market is experiencing growth, fueled by advancements in diagnostics, treatments, and patient awareness.

Market Insights and Drivers

The Non-metastatic Prostate Cancer (nmPC) market research highlights a growing demand for effective therapies that delay metastasis and improve survival outcomes. New therapeutic options, including androgen receptor inhibitors and next-generation hormonal therapies, have reshaped the treatment landscape. These advancements are complemented by better diagnostic tools like prostate-specific antigen (PSA) tests and imaging technologies, allowing for earlier detection and intervention.

The introduction of innovative drug combinations and tailored approaches for nmPC patients is driving the Non-metastatic Prostate Cancer (nmPC) market forward. Additionally, an aging global population, rising prostate cancer incidence, and increased awareness among healthcare providers and patients contribute significantly to market growth.

Epidemiology of nmPC

Prostate cancer is one of the most common cancers in men, with non-metastatic stages accounting for a significant portion of cases at diagnosis. Early-stage prostate cancer is more frequently diagnosed due to advancements in screening and awareness campaigns. Epidemiological studies indicate that while nmPC is common, the risk of progression to metastatic prostate cancer varies widely depending on factors such as PSA levels, Gleason scores, and patient age.

The growing focus on nmPC management is essential as patients with nmPC have a high likelihood of disease progression, particularly those with high-risk features. This has created a demand for novel therapies that effectively slow disease progression.

Competitive Landscape

Key Non-metastatic Prostate Cancer (nmPC) companies driving innovation in this market include Pfizer, Janssen Pharmaceuticals, AstraZeneca, and Bayer AG. These companies focus on developing androgen receptor pathway inhibitors and novel hormonal therapies to address unmet needs. Products like apalutamide, enzalutamide, and darolutamide have emerged as cornerstone treatments for nmPC, showing efficacy in delaying metastasis and improving survival.

Market Forecast - 2034

The Non-metastatic Prostate Cancer (nmPC) market forecast predicts robust growth through 2034, driven by increased adoption of advanced therapies, growing awareness, and improved diagnostic capabilities. The market is expected to expand globally, with the United States and Europe leading in terms of revenue, followed by emerging markets. Innovations in precision medicine and biomarkers for risk stratification will further refine treatment paradigms and drive the market forward.

In conclusion, the Non-metastatic Prostate Cancer (nmPC) market is poised for significant growth, supported by advancements in treatment and diagnostics. Continued investment in Non-metastatic Prostate Cancer (nmPC) market research and emerging therapies will enhance patient outcomes and reshape the future of nmPC care.

Latest Reports

0 notes

snehalblog · 3 days ago

Text

Non-Hodgkin Lymphoma Therapeutics Market: Exploring Advanced Therapies and Future Growth Potential - UnivDatos

According to a new report by UnivDatos Market Insights, Non-Hodgkin Lymphoma Therapeutics Market, is expected to reach USD 16524 Million in 2030 by growing at a CAGR of 7.7%. Non-Hodgkin lymphoma (NHL) therapeutics refers to the medical treatments and interventions aimed at managing and combating this type of cancer. Non-Hodgkin lymphoma is a group of cancers that affect the white blood cells called lymphocytes, which play a crucial role in our immune system. The development of innovative therapeutics for NHL has significantly improved patient outcomes. Therapeutic options for NHL include chemotherapy, immunotherapy, targeted therapy, radiation therapy, and stem cell transplantation. Chemotherapy involves the use of drugs to destroy cancer.

Request To Download Sample of This Strategic Report - https://univdatos.com/get-a-free-sample-form-php/?product_id=53024&utm_source=LinkSJ&utm_medium=Snehal&utm_campaign=Snehal&utm_id=snehal

The report suggests that the Rising Number Of Clinical Trials is one of the major factors driving the growth of the market during the forthcoming years. non-Hodgkin lymphoma therapeutics market has witnessed a significant growth in recent years, and one prominent driving factor behind this trend is the rising number of clinical trials conducted in this field. Clinical trials play a crucial role in the development and advancement of therapies for non-Hodgkin lymphoma, a type of cancer that affects the lymphatic system. These trials are designed to rigorously evaluate the safety and efficacy of new treatments, including novel drugs, immunotherapies, and targeted therapies specifically tailored for non-Hodgkin lymphoma. The increasing number of clinical trials indicates a growing interest and commitment from researchers, pharmaceutical companies, and healthcare professionals to find better treatment options for patients facing this challenging disease. For instance, in 2022, a study published in November projected that there would be a 43% increase in new non-Hodgkin lymphoma cases by 2040, which is expected to drive market growth due to rising adoption of NHL therapeutics.

Recent Technological Advancements:

Bispecific and trispecific antibodies have emerged as promising opportunities in the field of non-Hodgkin lymphoma (NHL) therapeutics. These antibodies are designed to target multiple antigens simultaneously, offering enhanced specificity and efficacy in treating NHL. Bispecific antibodies (BsAbs) are engineered to bind to two different antigens. In the context of NHL, BsAbs can be designed to target tumor-specific antigens present on lymphoma cells, as well as immune cells like T cells. By bridging tumor cells with immune cells, BsAbs can enhance the immune response against lymphoma, leading to improved tumor cell killing. One example of a bispecific antibody in NHL therapeutics is blinatumomab, which targets CD19 on lymphoma cells and CD3 on T cells.

Trispecific antibodies (TsAbs) take this concept further by targeting three different antigens simultaneously. In NHL therapeutics, TsAbs can target tumor cells, T cells, and accessory cells like natural killer (NK) cells. By engaging multiple immune cells, TsAbs can provoke a more robust immune reaction against lymphoma. TsAbs hold potential for even greater efficacy in treating NHL, and various research and development efforts are ongoing to explore their therapeutic benefits.

Immunotherapy Gaining Traction in Market

Immunotherapy is gaining attraction in non-Hodgkin lymphoma (NHL) treatment due to its promising potential and positive clinical outcomes. Here's why:

1. Targeted Approach: Immunotherapy specifically targets cancer cells by exploiting the body's immune system. It helps to identify and attack cancer cells more effectively while sparing healthy cells, minimizing potential side effects.

2. Improved Response Rates: Studies have shown that immunotherapy can significantly enhance response rates in non-Hodgkin lymphoma patients. Certain immunotherapy drugs, such as checkpoint inhibitors and CAR-T cell therapies, have demonstrated remarkable efficacy, especially in refractory or relapsed cases.

3. Long-term Benefits: Immunotherapy has shown the potential to induce durable responses. It can provide prolonged remission periods and even potential cures for some patients, leading to better long-term survival rates and improved quality of life.

Ask for Report Customization - https://univdatos.com/get-a-free-sample-form-php/?product_id=53024&utm_source=LinkSJ&utm_medium=Snehal&utm_campaign=Snehal&utm_id=snehal

Conclusion

The non-Hodgkin lymphoma therapeutics market is experiencing a paradigm shift with the development of targeted therapies, immunotherapies, and precision medicine. These advancements have significantly improved the treatment landscape for patients, providing them with more effective and personalized options. The increasing prevalence of non-Hodgkin lymphoma and the ongoing investments in research and development activities suggest a promising future for the market. However, further efforts are needed to enhance accessibility, affordability, and awareness of these innovative treatment modalities to ensure optimal patient care.

0 notes